SG11201807949WA - Engineered immunoglobulins with altered fcrn binding - Google Patents
Engineered immunoglobulins with altered fcrn bindingInfo
- Publication number
- SG11201807949WA SG11201807949WA SG11201807949WA SG11201807949WA SG11201807949WA SG 11201807949W A SG11201807949W A SG 11201807949WA SG 11201807949W A SG11201807949W A SG 11201807949WA SG 11201807949W A SG11201807949W A SG 11201807949WA SG 11201807949W A SG11201807949W A SG 11201807949WA
- Authority
- SG
- Singapore
- Prior art keywords
- international
- oslo
- blindern
- box
- pct
- Prior art date
Links
- 108060003951 Immunoglobulin Proteins 0.000 title abstract 2
- 102000018358 immunoglobulin Human genes 0.000 title abstract 2
- 229940072221 immunoglobulins Drugs 0.000 title abstract 2
- 101150050927 Fcgrt gene Proteins 0.000 title 1
- 230000008520 organization Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
- C07K16/081—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
- C07K14/7151—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for tumor necrosis factor [TNF], for lymphotoxin [LT]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/283—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against Fc-receptors, e.g. CD16, CD32, CD64
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
- C07K16/461—Igs containing Ig-regions, -domains or -residues form different species
- C07K16/462—Igs containing a variable region (Fv) from one specie and a constant region (Fc) from another
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/62—DNA sequences coding for fusion proteins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/524—CH2 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/526—CH3 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/72—Increased effector function due to an Fc-modification
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662307686P | 2016-03-14 | 2016-03-14 | |
| PCT/IB2017/000327 WO2017158426A1 (en) | 2016-03-14 | 2017-03-14 | Engineered immunoglobulins with altered fcrn binding |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201807949WA true SG11201807949WA (en) | 2018-10-30 |
Family
ID=58548768
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201807949WA SG11201807949WA (en) | 2016-03-14 | 2017-03-14 | Engineered immunoglobulins with altered fcrn binding |
Country Status (23)
| Country | Link |
|---|---|
| US (2) | US11319383B2 (ru) |
| EP (1) | EP3430039A1 (ru) |
| JP (2) | JP7155008B2 (ru) |
| KR (3) | KR20230069247A (ru) |
| CN (3) | CN109071631B (ru) |
| AU (1) | AU2017232546A1 (ru) |
| BR (1) | BR112018067897A2 (ru) |
| CA (1) | CA3011887A1 (ru) |
| CL (1) | CL2018002639A1 (ru) |
| CO (1) | CO2018009687A2 (ru) |
| CR (1) | CR20180445A (ru) |
| EA (1) | EA201892063A1 (ru) |
| GE (1) | GEP20217232B (ru) |
| IL (1) | IL261783B2 (ru) |
| MA (1) | MA43773A (ru) |
| MY (1) | MY195541A (ru) |
| PH (1) | PH12018501944A1 (ru) |
| SA (1) | SA518400022B1 (ru) |
| SG (1) | SG11201807949WA (ru) |
| TN (1) | TN2018000301A1 (ru) |
| UA (1) | UA125378C2 (ru) |
| WO (1) | WO2017158426A1 (ru) |
| ZA (1) | ZA202003612B (ru) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| UA125378C2 (uk) * | 2016-03-14 | 2022-03-02 | Універшітетет І Осло | МОДИФІКОВАНІ ІМУНОГЛОБУЛІНИ ЗІ ЗМІНЕНИМ ЗВ'ЯЗУВАННЯМ FcRn |
| US11858980B2 (en) | 2016-08-02 | 2024-01-02 | Visterra, Inc. | Engineered polypeptides and uses thereof |
| RS61883B1 (sr) | 2017-09-19 | 2021-06-30 | Tillotts Pharma Ag | Varijante antitela |
| EP3456738A1 (en) * | 2017-09-19 | 2019-03-20 | Tillotts Pharma Ag | Antibody variants |
| WO2020114616A1 (en) | 2018-12-07 | 2020-06-11 | Tillotts Pharma Ag | Topical treatment of immune checkpoint inhibitor induced diarrhoea, colitis or enterocolitis using antibodies and fragments thereof |
| EP3711772A1 (en) | 2019-03-20 | 2020-09-23 | Oslo Universitetssykehus HF | Recombinant proteins and fusion proteins |
| WO2023057595A1 (en) | 2021-10-06 | 2023-04-13 | Nordic Nanovector Asa | Humanized hh1 rew |
| WO2023079147A1 (en) | 2021-11-05 | 2023-05-11 | Oslo Universitetssykehus Hf | Iga fc and igg fc tandem protein constructs |
Family Cites Families (57)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CU22545A1 (es) | 1994-11-18 | 1999-03-31 | Centro Inmunologia Molecular | Obtención de un anticuerpo quimérico y humanizado contra el receptor del factor de crecimiento epidérmico para uso diagnóstico y terapéutico |
| US4436727A (en) | 1982-05-26 | 1984-03-13 | Ribi Immunochem Research, Inc. | Refined detoxified endotoxin product |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US4753894A (en) | 1984-02-08 | 1988-06-28 | Cetus Corporation | Monoclonal anti-human breast cancer antibodies |
| US4943533A (en) | 1984-03-01 | 1990-07-24 | The Regents Of The University Of California | Hybrid cell lines that produce monoclonal antibodies to epidermal growth factor receptor |
| JPS6147500A (ja) | 1984-08-15 | 1986-03-07 | Res Dev Corp Of Japan | キメラモノクロ−ナル抗体及びその製造法 |
| EP0173494A3 (en) | 1984-08-27 | 1987-11-25 | The Board Of Trustees Of The Leland Stanford Junior University | Chimeric receptors by dna splicing and expression |
| GB8422238D0 (en) | 1984-09-03 | 1984-10-10 | Neuberger M S | Chimeric proteins |
| JPS61134325A (ja) | 1984-12-04 | 1986-06-21 | Teijin Ltd | ハイブリツド抗体遺伝子の発現方法 |
| US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
| IL85035A0 (en) | 1987-01-08 | 1988-06-30 | Int Genetic Eng | Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same |
| CA1331443C (en) | 1987-05-29 | 1994-08-16 | Charlotte A. Kensil | Saponin adjuvant |
| US5057540A (en) | 1987-05-29 | 1991-10-15 | Cambridge Biotech Corporation | Saponin adjuvant |
| WO1989006692A1 (en) | 1988-01-12 | 1989-07-27 | Genentech, Inc. | Method of treating tumor cells by inhibiting growth factor receptor function |
| WO1991000906A1 (en) | 1989-07-12 | 1991-01-24 | Genetics Institute, Inc. | Chimeric and transgenic animals capable of producing human antibodies |
| DE69120146T2 (de) | 1990-01-12 | 1996-12-12 | Cell Genesys Inc | Erzeugung xenogener antikörper |
| EP0468520A3 (en) | 1990-07-27 | 1992-07-01 | Mitsui Toatsu Chemicals, Inc. | Immunostimulatory remedies containing palindromic dna sequences |
| WO1992003917A1 (en) | 1990-08-29 | 1992-03-19 | Genpharm International | Homologous recombination in mammalian cells |
| ES2246502T3 (es) | 1990-08-29 | 2006-02-16 | Genpharm International, Inc. | Animales no humanos transgenicos capaces de producir anticuerpos heterologos. |
| JP3854306B2 (ja) | 1991-03-06 | 2006-12-06 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフトング | ヒト化及びキメラモノクローナル抗体 |
| IL101715A (en) | 1991-05-02 | 2005-06-19 | Amgen Inc | Recombinant dna-derived cholera toxin subunit analogs |
| CA2085827C (en) | 1991-12-23 | 2003-10-14 | Lucas A. T. Hilgers | Adjuvant composition containing synthetic hydrophobic lipopolysaccharide |
| IT1253009B (it) | 1991-12-31 | 1995-07-10 | Sclavo Ricerca S R L | Mutanti immunogenici detossificati della tossina colerica e della tossina lt, loro preparazione ed uso per la preparazione di vaccini |
| HU219808B (hu) | 1992-06-25 | 2001-08-28 | Smithkline Beecham Biologicals S.A. | Adjuvánst tartalmazó vakcinakompozíció és eljárás annak előállítására |
| US5736137A (en) | 1992-11-13 | 1998-04-07 | Idec Pharmaceuticals Corporation | Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma |
| DE69405551T3 (de) | 1993-03-23 | 2005-10-20 | Smithkline Beecham Biologicals S.A. | 3-0-deazylierte monophosphoryl lipid a enthaltende impfstoff-zusammensetzungen |
| US6005099A (en) | 1993-11-17 | 1999-12-21 | Laboratoires Om S.A. | Glucosamine disaccharides, method for their preparation, pharmaceutical composition comprising same, and their use |
| GB9326253D0 (en) | 1993-12-23 | 1994-02-23 | Smithkline Beecham Biolog | Vaccines |
| GB9401182D0 (en) | 1994-01-21 | 1994-03-16 | Inst Of Cancer The Research | Antibodies to EGF receptor and their antitumour effect |
| CA2194761C (en) | 1994-07-15 | 2006-12-19 | Arthur M. Krieg | Immunomodulatory oligonucleotides |
| AUPM873294A0 (en) | 1994-10-12 | 1994-11-03 | Csl Limited | Saponin preparations and use thereof in iscoms |
| UA56132C2 (ru) | 1995-04-25 | 2003-05-15 | Смітклайн Бічем Байолоджікалс С.А. | Композиция вакцины (варианты), способ стабилизации qs21 по отношению к гидролизу (варианты), способ приготовления вакцины |
| CA2222231A1 (en) | 1995-06-07 | 1996-12-19 | Imclone Systems Incorporated | Antibody and antibody fragments for inhibiting the growth of tumors |
| ATE292980T1 (de) | 1996-10-11 | 2005-04-15 | Univ California | Immunostimulierende oligonucleotidekonjugate |
| US6235883B1 (en) | 1997-05-05 | 2001-05-22 | Abgenix, Inc. | Human monoclonal antibodies to epidermal growth factor receptor |
| GB9711990D0 (en) | 1997-06-11 | 1997-08-06 | Smithkline Beecham Biolog | Vaccine |
| AU734180B2 (en) | 1997-08-29 | 2001-06-07 | Antigenics Llc | Compositions comprising the adjuvant qs-21 and polysorbate or cyclodextrin as excipient |
| GB9718901D0 (en) | 1997-09-05 | 1997-11-12 | Smithkline Beecham Biolog | Vaccine |
| EP1009382B1 (en) | 1997-09-05 | 2003-06-18 | GlaxoSmithKline Biologicals S.A. | Oil in water emulsions containing saponins |
| NL1011002C2 (nl) * | 1999-01-12 | 2000-07-20 | Univ Eindhoven Tech | Versterkerschakeling. |
| US6737056B1 (en) * | 1999-01-15 | 2004-05-18 | Genentech, Inc. | Polypeptide variants with altered effector function |
| HUP0104865A3 (en) | 1999-01-15 | 2004-07-28 | Genentech Inc | Polypeptide variants with altered effector function |
| ES2350306T3 (es) | 1999-02-26 | 2011-01-20 | Novartis Vaccines And Diagnostics, Inc. | Uso de bioadhesivos y adyuvantes para la administración de antígenos por vía mucosa. |
| EP1266009B1 (en) | 2000-02-25 | 2008-12-31 | THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES | ANTI-EGFRvIII SCFVS WITH IMPROVED CYTOTOXICITY AND YIELD, IMMUNOTOXINS BASED THEREON, AND METHODS OF USE THEREOF |
| CN1239701C (zh) | 2000-05-19 | 2006-02-01 | 梨树化学株式会社 | 抗表皮生长因子受体的人源化抗体 |
| US20050221284A1 (en) * | 2001-07-17 | 2005-10-06 | Taylor Ronald P | Heteropolymer complexes and methods for their use |
| EP1434602B1 (en) | 2001-10-06 | 2014-12-17 | Merial Limited | CpG plus oil in water emulsion as adjuvant system for truncated bovine herpesvirus-1 glycoprotein D |
| CN101124245A (zh) * | 2003-11-12 | 2008-02-13 | 比奥根艾迪克Ma公司 | 新生儿Fc受体(FcRn)-结合多肽变体、二聚体Fc结合蛋白及其相关方法 |
| CA2545603A1 (en) * | 2003-11-12 | 2005-05-26 | Biogen Idec Ma Inc. | Neonatal fc receptor (fcrn)-binding polypeptide variants, dimeric fc binding proteins and methods related thereto |
| DOP2006000029A (es) | 2005-02-07 | 2006-08-15 | Genentech Inc | Antibody variants and uses thereof. (variantes de un anticuerpo y usos de las mismas) |
| KR20190025057A (ko) * | 2008-10-14 | 2019-03-08 | 제넨테크, 인크. | 이뮤노글로불린 변이체 및 그의 용도 |
| IT1395574B1 (it) | 2009-09-14 | 2012-10-16 | Guala Dispensing Spa | Dispositivo di erogazione |
| GB201112429D0 (en) | 2011-07-19 | 2011-08-31 | Glaxo Group Ltd | Antigen-binding proteins with increased FcRn binding |
| TW201817745A (zh) * | 2011-09-30 | 2018-05-16 | 日商中外製藥股份有限公司 | 具有促進抗原清除之ＦｃＲｎ結合域的治療性抗原結合分子 |
| BR112014026740B1 (pt) * | 2012-04-27 | 2022-10-04 | Bioatla, Llc | Anticorpo, composição, método para fornecer um anticorpo com adcc realçada, e, uso de um anticorpo |
| AU2015248785A1 (en) | 2014-04-16 | 2016-11-24 | Ucb Biopharma Sprl | Multimeric Fc proteins |
| UA125378C2 (uk) * | 2016-03-14 | 2022-03-02 | Універшітетет І Осло | МОДИФІКОВАНІ ІМУНОГЛОБУЛІНИ ЗІ ЗМІНЕНИМ ЗВ'ЯЗУВАННЯМ FcRn |
-
2017
- 2017-03-14 UA UAA201809852A patent/UA125378C2/uk unknown
- 2017-03-14 EA EA201892063A patent/EA201892063A1/ru unknown
- 2017-03-14 MY MYPI2018001550A patent/MY195541A/en unknown
- 2017-03-14 CA CA3011887A patent/CA3011887A1/en active Pending
- 2017-03-14 AU AU2017232546A patent/AU2017232546A1/en active Pending
- 2017-03-14 CN CN201780017321.4A patent/CN109071631B/zh active Active
- 2017-03-14 MA MA043773A patent/MA43773A/fr unknown
- 2017-03-14 CR CR20180445A patent/CR20180445A/es unknown
- 2017-03-14 KR KR1020237014765A patent/KR20230069247A/ko not_active Application Discontinuation
- 2017-03-14 JP JP2018548847A patent/JP7155008B2/ja active Active
- 2017-03-14 SG SG11201807949WA patent/SG11201807949WA/en unknown
- 2017-03-14 TN TNP/2018/000301A patent/TN2018000301A1/en unknown
- 2017-03-14 CN CN202310764145.8A patent/CN116789830A/zh active Pending
- 2017-03-14 US US16/085,254 patent/US11319383B2/en active Active
- 2017-03-14 KR KR1020237014766A patent/KR20230062894A/ko not_active Application Discontinuation
- 2017-03-14 KR KR1020187023624A patent/KR20180127320A/ko not_active IP Right Cessation
- 2017-03-14 EP EP17717856.3A patent/EP3430039A1/en active Pending
- 2017-03-14 BR BR112018067897A patent/BR112018067897A2/pt unknown
- 2017-03-14 CN CN202310359292.7A patent/CN116239693A/zh active Pending
- 2017-03-14 WO PCT/IB2017/000327 patent/WO2017158426A1/en active Application Filing
- 2017-03-14 GE GEAP201714875A patent/GEP20217232B/en unknown
-
2018
- 2018-09-11 PH PH12018501944A patent/PH12018501944A1/en unknown
- 2018-09-13 SA SA518400022A patent/SA518400022B1/ar unknown
- 2018-09-13 IL IL261783A patent/IL261783B2/en unknown
- 2018-09-14 CO CONC2018/0009687A patent/CO2018009687A2/es unknown
- 2018-09-14 CL CL2018002639A patent/CL2018002639A1/es unknown
-
2020
- 2020-06-17 ZA ZA2020/03612A patent/ZA202003612B/en unknown
-
2022
- 2022-04-12 US US17/719,227 patent/US20220348690A1/en active Pending
- 2022-10-05 JP JP2022161176A patent/JP2022188205A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11201807949WA (en) | Engineered immunoglobulins with altered fcrn binding | |
| SG11201811431VA (en) | Multispecific antibodies against cd40 and cd137 | |
| SG11201903857UA (en) | Antibodies to pd-1 and uses thereof | |
| SG11201907753TA (en) | Bispecific binding molecules that are capable of binding cd137 and tumor antigens, and uses thereof | |
| SG11201909868YA (en) | Compositions and methods of treating huntington's disease | |
| SG11201806624XA (en) | Deposition of molybdenum thin films using a molybdenum carbonyl precursor | |
| SG11201806992VA (en) | Antibodies to tigit | |
| SG11201809625RA (en) | 1-tetrahydropyranylcarbonyl-2,3-dihydro-1h-indole compounds for treating cancer | |
| SG11201906192SA (en) | Methods of treating cancer with anti-pd-1 antibodies | |
| SG11201807252QA (en) | Anti-lag-3 antibodies | |
| SG11201909081YA (en) | Anti-ilt4 antibodies and antigen-binding fragments | |
| SG11201910027YA (en) | Bispecific antibody against ox40 and ctla-4 | |
| SG11201908088RA (en) | Antibodies against pd-l1 | |
| SG11201804086VA (en) | Methods and compositions for nucleic acid analysis | |
| SG11201900746RA (en) | Engineered antibodies and other fc-domain containing molecules with enhanced agonism and effector functions | |
| SG11201809830WA (en) | Selective reduction of cysteine-engineered antibodies | |
| SG11201909011PA (en) | Niraparib compositions | |
| SG11201903060XA (en) | Metallocene catalysts, catalyst systems, and methods for using the same | |
| SG11201408678WA (en) | Catalysts and methods for polyester production | |
| SG11201407859YA (en) | Methods of treating cancer using pd-l1 axis binding antagonists and vegf antagonists | |
| SG11201908056QA (en) | Anti-par2 antibodies and uses thereof | |
| SG11201908326YA (en) | Methods of treating neurodegenerative diseases | |
| SG11201805001UA (en) | Method of treating influenza a | |
| SG11202000333UA (en) | Bicyclic ketone compounds and methods of use thereof | |
| SG11201803918VA (en) | Production of steviol glycosides in recombinant hosts |